Clinical Relevance of C-Reactive Protein During Follow-Up of Patients With Acute Coronary Syndromes in the Aggrastat-to-Zocor Trial | Zendy

David A. Morrow | Zendy; James A. de Lemos | Zendy; Marc S. Sabatine | Zendy; Stephen D. Wiviott | Zendy; Michael A. Blazing | Zendy; Amy M. Shui | Zendy; Nader Rifai | Zendy; Robert M. Califf | Zendy; Eugene Braunwald | Zendy

Open Access

Clinical Relevance of C-Reactive Protein During Follow-Up of Patients With Acute Coronary Syndromes in the Aggrastat-to-Zocor Trial

Author(s) -

David A. Morrow,

James A. de Lemos,

Marc S. Sabatine,

Stephen D. Wiviott,

Michael A. Blazing,

Amy M. Shui,

Nader Rifai,

Robert M. Califf,

Eugene Braunwald

Publication year - 2006

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.106.628909

Subject(s) - medicine , c reactive protein , acute coronary syndrome , simvastatin , statin , diabetes mellitus , gastroenterology , coronary artery disease , surgery , cardiology , myocardial infarction , endocrinology , inflammation

Elevated levels of high-sensitivity C-reactive protein (hsCRP) are associated with higher risk of adverse outcomes in patients at risk for or with established coronary artery disease. Retrospective analyses suggest that this risk may be modified with statin therapy. However, a role for hsCRP in monitoring the success of therapy remains uncertain.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research